These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 27002793)

  • 1. Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
    Ciprero KL; Marchese RD; Richard P; Baudin M; Sterling TM; Manoff SB; Radley D; Stek JE; Soubeyrand B; Grabenstein JD; Samson SI; Musey LK
    Hum Vaccin Immunother; 2016 Aug; 12(8):2135-2141. PubMed ID: 27002793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study.
    Namkoong H; Funatsu Y; Oishi K; Akeda Y; Hiraoka R; Takeshita K; Asami T; Yagi K; Kimizuka Y; Ishii M; Tasaka S; Suzuki Y; Iwata S; Betsuyaku T; Hasegawa N
    Vaccine; 2015 Jan; 33(2):327-32. PubMed ID: 25448102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults.
    Grabenstein JD; Musey LK
    Vaccine; 2014 May; 32(21):2399-405. PubMed ID: 24637174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response to pneumococcal conjugate vaccination in asplenic individuals.
    Stanford E; Print F; Falconer M; Lamden K; Ghebrehewet S; Phin N; Baxter D; Helbert M; McCann R; Andrews N; Balmer P; Borrow R; Kaczmarski E
    Hum Vaccin; 2009 Feb; 5(2):85-91. PubMed ID: 18758242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional immune responses to twelve serotypes after immunization with a 23-valent pneumococcal polysaccharide vaccine in older adults.
    Ahn JG; Kim HW; Choi HJ; Lee JH; Kim KH
    Vaccine; 2015 Sep; 33(38):4770-5. PubMed ID: 26277073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a Multiplexed Opsonophagocytic Assay for 11 Additional Pneumococcal Serotypes and Its Application to Functional Antibody Evaluation Induced by Pneumococcal Polysaccharide Vaccine.
    Cha J; Kim HW; Lee JH; Lee S; Kim KH
    J Korean Med Sci; 2018 Dec; 33(51):e340. PubMed ID: 30546285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults.
    Thompson A; Lamberth E; Severs J; Scully I; Tarabar S; Ginis J; Jansen KU; Gruber WC; Scott DA; Watson W
    Vaccine; 2019 Sep; 37(42):6201-6207. PubMed ID: 31495592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions.
    Jallow S; Madhi SA; Madimabe R; Sipambo N; Violari A; Kala U; Petersen K; Naidoo S; Verwey C; Moore DP; Nunes MC
    Vaccine; 2017 Aug; 35(34):4321-4329. PubMed ID: 28688781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease.
    Kantsø B; Halkjær SI; Thomsen OØ; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Vaccine; 2015 Oct; 33(41):5464-5469. PubMed ID: 26275480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 22-plex chemiluminescent microarray for pneumococcal antibodies.
    Pickering JW; Hoopes JD; Groll MC; Romero HK; Wall D; Sant H; Astill ME; Hill HR
    Am J Clin Pathol; 2007 Jul; 128(1):23-31. PubMed ID: 17580269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.
    Moberley S; Licciardi PV; Balloch A; Andrews R; Leach AJ; Kirkwood M; Binks P; Mulholland K; Carapetis J; Tang MLK; Skull S
    Vaccine; 2017 May; 35(22):2908-2915. PubMed ID: 28455171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
    Li G; Ren T; Zhang H; Ti J; Chang X; Yin S; Guan Y; Liu G; Liang Q; Liu J
    Vaccine; 2024 Oct; 42(24):126209. PubMed ID: 39217777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibodies to pneumococcal conjugate vaccine compared to polysaccharide vaccine in patients with Crohn's disease - one year follow up.
    Kantsø B; Halkjær SI; Østergaard Thomsen O; Belard E; Gottschalck IB; Jørgensen CS; Krogfelt KA; Slotved HC; Ingels H; Petersen AM
    Infect Dis (Lond); 2019 Sep; 51(9):651-658. PubMed ID: 31290715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.